To this end, ZED1227 (TAK-227), a selective oral TG2 inhibitor, was administered to CeD patients at one of three doses (10, 50 or 100 mg) alongside a 3 g gluten challenge for 6 weeks. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.